cervical cancer
Conditions
Interventions
experimental group:Estriol suppository
Sponsors
The Second Xiangya Hospital, Central South University
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Inclusion criteria for prospective studies 1. Patients with genitourinary tract atrophy and (or) atrophic vaginitis with more than one year or colposcopy; patients with 2. Cytology ASCUS, LSIL and or HPV high risk positive or sexual bleeding. Inclusion criteria for retrospective studies 1. Patients with urogenital tract atrophy and (or) atrophic vaginitis with complete patient medical records, colposcopy and biopsy pathological diagnosis; 2. menopause for more than one year or surgical menopause for colposcopy; 3. cytology for ASCUS, LSIL, or HPV high risk positive or sexual bleeding.
Exclusion criteria
Exclusion criteria: 1. Allergic to any component of estriol supposition; 2. Patients with venous or arterial thromboembolic diseases; 3. Patients who may or have breast cancer or estrogen-dependent tumors; 4. Patients with vaginal bleeding of unknown cause; 5. Patients with a history of other estrogen use.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of adequate colposcopy; | — |
Secondary
| Measure | Time frame |
|---|---|
| Number and proportion of people visible in the Squamous Column Junction (SCJ);Number and proportion of visible (TZ type I/II) in translational;Conformity rate between the results of the colposcopy and histopathological diagnosis CR;IFCPC-based colposcopic diagnosis: number and proportion of patients with each lesion grade, type, and number;Number and proportion of biopsy pathology types by tissue;Patient pain score PS;patient satisfaction; | — |
Countries
China
Contacts
Public ContactXiaomeng Xia
The Second Xiangya Hospital, Central South University
Outcome results
None listed